Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Emily Sumpena, Ioulia Vogiatzi, Arsh Patel, Heather Walker, Jenna Mahns, Robert Redd, Philippe Armand, Reid Merryman, Mark Murakami
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417009726
Cites:
Cited by:
Related to: